MedTrace Logo

Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions

NCT00836056 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-08-19

Study results available
· View outcomes & findings →

Summary

The objective of this study is to compare the rate and extent of absorption of clindamycin 300 mg capsules (test) versus Cleocin HCl (reference), administered as 1 x 300 mg capsule under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Clindamycin 300 mg capsule

1 x 300 mg

DRUG

Cleocin HCl 300 mg capsules

1 x 300 mg

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    lead INDUSTRY

Principal Investigators

  • Benoit Girard, M.D. · Anapharn Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2003-11-30
Completion
2003-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00836056 on ClinicalTrials.gov